Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/29620
Title: | Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial. | Authors: | VRANCKX, Pascal Valgimigli, Marco Eckardt, Lars Tijssen, Jan Lewalter, Thorsten Gargiulo, Giuseppe Batushkin, Valerii Campo, Gianluca Lysak, Zoreslava Vakaliuk, Igor Milewski, Krzysztof Laeis, Petra Reimitze, Paul-Egbert Smolnik, Rüdiger Zierhut, Wolfgang Goette, Andreas |
Issue Date: | 2019 | Source: | The Lancet, 394 (10206), p. 1335-1343 | Abstract: | Background We aimed to assess the safety of edoxaban in combination with P2Y12 inhibition in patients with atrial fibrillation who had percutaneous coronary intervention (PCI).Methods ENTRUST-AF PCI was a randomised, multicentre, open-label, non-inferiority phase 3b trial with masked outcome evaluation, done at 186 sites in 18 countries. Patients had atrial fibrillation requiring oral anticoagulation, were aged at least 18 years, and had a successful PCI for stable coronary artery disease or acute coronary syndrome. Participants were randomly assigned (1:1) from 4 h to 5 days after PCI using concealed, stratified, and blocked web-based central randomisation to either edoxaban (60 mg once daily) plus a P2Y12 inhibitor for 12 months or a vitamin K antagonist (VKA) in combination with a P2Y12 inhibitor and aspirin (100 mg once daily, for 1–12 months). The edoxaban dose was reduced to 30 mg per day if one or more factors (creatinine clearance 15–50 mL/min, bodyweight ≤60 kg, or concomitant use of specified potent P-glycoprotein inhibitors) were present. The primary endpoint was a composite of major or clinically relevant non-major (CRNM) bleeding within 12 months. The primary analysis was done in the intention-to-treat population and safety was assessed in all patients who received at least one dose of their assigned study drug. This trial is registered with ClinicalTrials.gov, NCT02866175, is closed to new participants, and follow-up is completed.Findings From Feb 24, 2017, through May 7, 2018, 1506 patients were enrolled and randomly assigned to the edoxaban regimen (n=751) or VKA regimen (n=755). Median time from PCI to randomisation was 45·1 h (IQR 22·2–76·2). Major or CRNM bleeding events occurred in 128 (17%) of 751 patients (annualised event rate 20·7%) with the edoxaban regimen and 152 (20%) of 755 patients (annualised event rate 25·6%) patients with the VKA regimen; hazard ratio 0·83 (95% CI 0·65–1·05; p=0·0010 for non-inferiority, margin hazard ratio 1·20; p=0·1154 for superiority).Interpretation In patients with atrial fibrillation who had PCI, the edoxaban-based regimen was non-inferior for bleeding compared with the VKA-based regimen, without significant differences in ischaemic events | Notes: | Vranckx, P (reprint author), Hasselt Univ, Fac Med & Life Sci, Dept Cardiol & Intens Care, Jessa Ziekenhuis, Hasselt, Belgium Goette, A (reprint author), St Vincenz Hosp, Cardiol & Intens Care Med, Paderborn, Germany. pascal.vranckx@jessazh.be; andreas.goette@vincenz.de | Document URI: | http://hdl.handle.net/1942/29620 | ISSN: | 0140-6736 | e-ISSN: | 1474-547X | DOI: | 10.1016/S0140-6736(19)31872-0 | ISI #: | 000489613700028 | Rights: | 2019 Elsevier Ltd. All rights reserved | Category: | A1 | Type: | Journal Contribution | Validations: | ecoom 2020 |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
34386.pdf Restricted Access | Peer-reviewed author version | 225.94 kB | Adobe PDF | View/Open Request a copy |
1-s2.0-S0140673619318720-main.pdf Restricted Access | Published version | 1.01 MB | Adobe PDF | View/Open Request a copy |
SCOPUSTM
Citations
101
checked on Sep 3, 2020
WEB OF SCIENCETM
Citations
452
checked on Aug 27, 2024
Page view(s)
108
checked on Jul 20, 2022
Download(s)
94
checked on Jul 20, 2022
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.